Podcast appearances and mentions of Ben Adams

The mighty Ben Adams introduces our first two-part Obbocast as our Executive Producer Rebecca Deeprose discusses her favourite Sun Hill copper in glorious detail with Patrick! Between them, this talented pair of sleuths begin to collate their all-time Top 10 Deakin stories, focusing initially on his early episodes from his unique debut in "Unfinished Business" and his famous encounter with David Tennant in "Deadline". What are some of your favourite Chrissy D moments? Enjoy the first five minutes of this latest release and remember you can unlock the full Obbocasts and hundreds of hours of content for just £2.99 on patreon.com/thebillpodcast - We would REALLY appreciate your support. The Bill Podcast is brought to you in proud association with georgefairbrother.com shop.saturdaymorningpress.co.uk vanguardcomics.co.uk gibconsultancy.co.uk and mcr-seo.com

The brotherhood of South River boys lacrosse takes center stage as the senior class joins Hawk Talk to reflect on a shared goal: a state championship. Trevor Phipps, Ben Adams, Ethan Marcian, Brody Miller, DaKhari Wallace, Will McCormick, Jacob Dillon, Sam Sollers, Andrew Patterson, Colin Burke, Conner Campbell, and Donovan Driscoll talk about growing up together on the field, Coach Campbell's impact, and the unforgettable moments that have defined their journey. With senior night on the horizon, this group is focused on leaving a lasting legacy.Hawk Talk is hosted by Tom Frank, Jaden McDuffie and Grey Frank, and brought to you by Chad's BBQ, Merrick Creative, and Maryland Remodeling Expert. Don't hesitate to contact us through Instagram @SRHawkTalk or by email at SRHawkTalk@gmail.com. Please reach out, send updates after games, let us know about fundraisers, big events, etc. This show is only as good as what we know. So get involved! Subscribe, Listen and Share the show on Apple, Spotify or wherever you listen to podcasts, leave us a rating on Apple, help support the show at https://srhawktalk.buzzsprout.com, and spread the word Seahawk Nation. #WERSRSend us a textSupport the show

#364 - A Bordo RingDa curioso supporter, a "secondo" sul ring.Da spettatore, a infermiere.Da "non so neanche come si chiama", a "spalla".Quando sono uscito di casa Mercoledì sera, non mi sarei neanche lontanamente potuto immaginare quello che avrei vissuto. E' stato un vortice di sensazioni super-intense, dal primo minuto in motorino, all'ultimo... sorpassando e vedendo un biondo inglese sorridente.-----------------------Video dell'incontro Isamu vs Lucas: https://fb.watch/ytSBKiV4lD/ (8 min)_______________Info Utili• Sostieni questo podcast:Ottieni feedback, ricevi consigli sul tuo progetto onlinehttps://Patreon.com/Robin_Good•  Musica di questa puntata:"I Found Love" by Ben Adams disponibile su Upbeat•  Nella foto di copertina:Ring Pre-Incontro Lucas vs. Isamu. PhetchBuncha Stadium. Chaweng, Koh Samui. Mercoledì 19 Marzo 2025. Thailandia•  Nuovo canale Instagram (dalla Thailandia - ciò che vedono i miei occhi: momenti non in posa):https://instagram.com/giggi_canali • Dammi feedback:Critiche, commenti, suggerimenti, idee e domande unendoti al gruppo Telegram https://t.me/@RobinGoodPodcastFeedback• Ascolta e condividi questo podcast:https://www.spreaker.com/show/dabrandafriendArchivio completo organizzato per temi:https://start.me/p/kxENzk/da-brand-a-friend-archivio-podcast• Seguimi su Telegram:https://t.me/RobinGoodItalia• Newsletter in Inglese:https://robingood.substack.com - Fuoco su costruire fiducia per chi fa l'imprenditore onlinehttps://goodtools.substack.com - Tool alternativi a costo zerohttps://curationmonetized.substack.com - Monetizzare organizzando informazioni.

David Gornoski sits down with Idaho State Senator and Marine Corps Veteran Ben Adams for a conversation on the Defend the Guard Act, how America can have a pro-life future, the Marriage Liberation Act, how government ruined food, MAHA, and more. Follow Ben Adams on X here. Follow David Gornoski on X here. Visit aneighborschoice.com for more

Ben Adams, the founder and CEO of Ten Capital Management, as well as founder and chairman emeritus of the Defined Contribution Real Estate Council (DCREC), joins us to discuss his organization's progress in adding real estate investment options to DC plans. (11/2024)

Ben Adams, the founder and CEO of Ten Capital Management, as well as founder and chairman emeritus of the Defined Contribution Real Estate Council (DCREC), joins us to discuss his organization's progress in adding real estate investment options to DC plans. (11/2024)

Mike Chmielewski talks with Ben Adams, Soldotna rancher and new owner of the only USDA certified meat processing facility in southcentral Alaska. Listen to his story and plans for the future.

https://www.instagram.com/woodenspoonministry/0:00 The Origin of Wooden Spoon Ministry04:22 First Steps and Viral Success05:45 Street Interviews and Initial Challenges08:39 Handling Aggressive Encounters13:49 The Power of Social Media in Ministry21:41 Crafting Effective Outreach Questions23:40 Reflecting on Viral Success23:59 Exploring Faith and Beliefs24:45 The Power of Public Interviews25:27 Content Creation Strategies26:55 Engaging with Different Audiences31:31 Balancing Ministry and Livelihood35:45 Encouragement for Aspiring Creators38:13 Inspiring Testimonies and Final Thoughts

Ben Adams proposes to reduce Ethereum's slot time. Aztec Network releases its roadmap to mainnet. Aave proposes to launch native GHO on Base. And UniswapX goes live on mobile. Read more: https://ethdaily.io/568

08th Oct: Blockchain DXB Podcast

In this week's episode of "The Top Line," we're recapping and discussing the major trends from Digitial Pharma East, which took place in Philadelphia last week. The event brought together marketing experts from across the life sciences industry.  Fierce Pharma Marketing's Andrea Park and Ben Adams talk about major trends from the event that came up in conversations, including the complicated current attitudes toward artificial intelligence in this space.  They also highlight some winners of the annual Fierce Pharma Marketing Awards, held on the final night of Digital Pharma East.   To learn more about the topics in this episode:  Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing Pfizer, Sanofi, GSK among the winners of the 2024 Fierce Pharma Marketing Awards Two-thirds of top 20 pharmas have banned ChatGPT—and many in life sci call AI 'overrated,' survey finds See omnystudio.com/listener for privacy information.

Welcome to the extended finale of this three-course feast of an interview with the wonderful Pal Aron! Pal and Natalie continue to discuss his time at Sun Hill, where Natalie asks him to share some memories of some of their lovely colleagues... Pal also reflects on his time on the cobbles, his role in the BAFTA-winning sitcom Stella, his recent writing work, a dream job on the big screen AND they both share stories about the music icon Prince! The Bill Podcast is brought to you in association with georgefairbrother.com shop.saturdaymorningpress.co.uk cityfiction.co.uk and vanguardcomics.co.uk The Bill Podcast is produced by Oliver Crocker and co-produced by Ben Adams, Glen Allen, Rob Cook, Glenn Cooney, Georgina Dark, Sarah Keiper, Bryony Kelly, Maz Mirabilis, Alex Mockler and Simon Wolf Our Executive Producers are Isobel Allan, Ben Ashmore, Mark Bennett, Alana Dewar, Andrew Diack, Paul Dunn, Tony Drury, Dan Evans, George Fairbrother, Luke Heagerty, Robert Hoegger, Edward Kellett, James Ledain, Thomas Jhonston, Lucy McNeil, Gary Moncur, Danny Morris, Steph Morris, Claire Norbury, Laura Pini-Fay, Alistair Rigley, Michael Seely, Tom Sherrington, Angel Stannard, Paul Statter, Patrick Stratford, Michael While and Sarah Went. Huge thanks to all our lovely Patrons who make The Bill Podcast possible. If you'd like to add your name to the credits and support the podcast, join the investigation at patreon.com/thebillpodcast

Welcome back to Part 2 of Natalie's Bill Podcast interview with her friend and colleague Pal Aron (DC Brandon Kane) This time Pal shares memories of growing up in Birmingham, discovering acting, his impressive work in the theatre and joining the BBC's flagship drama series Casualty. They also begin to talk about Pal's time as DC Brandon Kane in The Bill and discuss THAT Cathy Bradford storyline. We're also thrilled to introduce our new sponsor vanguardcomics.co.uk who on Sunday April 14th are hosting Gosport Comic Con, where you can meet Natalie Roles, Larry Dann, Raji James and Mark Wingett from The Bill, alongside Doctor Who stars Colin Baker, Nicola Bryant and Sophie Aldred. Find out more and book your tickets via https://www.vanguardcomics.co.uk/comic-con-2024 The Bill Podcast is brought to you in association with georgefairbrother.com shop.saturdaymorningpress.co.uk cityfiction.co.uk and vanguardcomics.co.uk The Bill Podcast is produced by Oliver Crocker, co-produced by Ben Adams, Glen Allen, Rob Cook, Georgina Dark, Sarah Keiper, Maz Mirabilis, Alex Mockler and Simon Wolf. Executive Produced by Isobel Allan, Ben Ashmore, Mark Bennett, Alana Dewar, Andrew Diack, Paul Dunn, Tony Drury, Dan Evans, George Fairbrother, Luke Heagerty, Alan Hunting, Thomas Jhonston, Edward Kellett, James Ledain, Lucy McNeil, Gary Moncur, Danny Morris, Steph Morris, Claire Norbury, Laura Pini-Fay, Alistair Rigley, Michael Seely, Tom Sherrington, Angel Stannard, Paul Statter, Patrick Stratford, Michael While and Sarah Went. The music is composed by Matthew Anniss

City Church AC Pastor Ben Adams 11:00 AM Navigating Intrusive Thoughts

Today's episode is proudly presented by our main sponsors at Moon Golf! We are joined on Episode 87 by aspiring professional golfer Ben Adams. Ben takes us on his journey so far while he documents his ongoing process of chasing every golfers dream.

City Church AC Pastor Ben Adams 11:00 AM In Times of Injustice, God's Justice, Will Ultimately Win Out

Ben Adams has written a brand new score for Police Cops The Musical.The show recently opened  at the Southwark Playhouse following a run at the Edinburgh Fringe Festival.Ben also co-wrote the beloved musical Eugenius which premiered at the London Palladium ahead of two runs at The Other Palace and its most recent revival at the Turbine Theatre. Ben is a member of the group A1 who won a BRIT Award in 2001 for Best Newcomer and have had two number one singles. He first ventured into theatre as a performer, starring in pantomime before playing Nick Hurley in the 2017 UK & Ireland tour of Flashdance The Musical. Most recently Ben returned to the stage as Galileo in the Norwegian production of We Will Rock You in Oslo, when he now lives with his family.Ben continues to tour the world with A1 and the band Subwoolfer whilst undertaking various writing projects within the music world and beyond. In this episode, Ben  reveals how he ventured into theatre and ended up writing Eugenius and why he still has big aspirations for the show. He also discusses all things Police Cops, his writing process and lots more. Police Cops The Musical runs at the Southwark Playhouse  Borough until 14th October 2023. Visit www.southwarkplayhouse.co.uk for info and tickets. Hosted by Andrew Tomlins  @AndrewTomlins32  Thanks for listening! Email: andrew@westendframe.co.uk Visit westendframe.co.uk for more info about our podcasts.  

“If I wanted to actually, earn enough money to buy a house or start a family or something, I'm going to need to, to earn more than just what I make as a barista, or even this the sporadic performing arts work that came in. So I made a decision, I was either going to become a laborer or like a chippy, or a carpenter, or actually start my own business.” -Ben Adams Welcome to a brand-new episode of the Woodpreneur Podcast. Today, your host Steve Larosiliere is joined by Ben Adams from Ben Adams Studio. Ben's journey into the world of woodworking is a testament to the power of passion and the pursuit of creativity. From a young age, he was drawn to the art of making, tinkering, and building. His grandfather's shed served as a haven for his curious spirit, igniting a spark that would eventually shape his destiny. Initially studying theater and performing arts, Ben found solace in crafting wood during his spare time. As he honed his skills and created beautiful pieces year after year, his love for woodworking never waned. A pivotal moment arrived during the challenging days of the pandemic, when the performing arts industry took an unexpected pause. This interlude allowed Ben to fully embrace his woodworking talents and turn them into a flourishing business. Listen now and get the whole story! “ So having having low prices, but it's really hard when you start out having low prices to then have, when you're getting your business going to actually then try and raise the prices is a lot harder than starting out at a reasonable price, and then maybe, maybe getting cheaper as you get more efficient.” - Ben Adams Building Bridges: Challenges and Triumphs Transitioning from a garage-based operation to a commercial workshop poses its share of challenges. Ben's journey demonstrates the importance of aligning vision with growth. For him, one of the pivotal challenges was pricing his art accurately. Overcoming the tendency to undervalue his work and understanding the intrinsic worth of his craftsmanship became a crucial step towards building a sustainable business model.  Designing for Generations: A Legacy of Craftsmanship At the core of Ben's work lies the joy of crafting pieces that will stand the test of time and resonate through generations. It's the beauty of knowing that the dining tables he creates will witness family gatherings, celebrate milestones, and serve as a tangible link between the past and the present. His pieces tell stories - of the trees that stood for years, the hands that shaped them, and the moments they become part of. In an age of mass-produced items, Ben's dedication to sustainable practices and handcrafted excellence shines as a beacon of authenticity. His journey reminds us that behind every piece of art lies a creator's heart, a dedication to preserving traditions, and a commitment to crafting a sustainable future. In Montville, Ben Adams Studio is more than a workshop; it's a testament to the beauty of transforming nature's gifts into functional art that resonates deeply with our souls. As Ben continues to craft his legacy, he invites us to pause and reflect on the stories we can infuse into the objects we create, the importance of sustainable practices, and the timeless beauty that can emerge from a single piece of wood. “I would even take some of the excess money and hire a virtual assistant, like do it for a week or 225 in the morning. 25 In the evening, right? instead of maybe 50, do 4020 In the morning, 20 In the evening, friend 20 People in the morning on Facebook, 20 people in the evening, so I would do the DMing on Instagram, and on Facebook, I would you friend 50 people a day, join the groups participate, all that sort of stuff, and then go all in and don't stop literally don't stop” -Steve Larosiliere Want to get in touch with Ben Adams? Contact him through: Instagram: https://www.instagram.com/benadamsfurniture/ Website: https://www.benadams.studio/

Ulvene i Subwoolfer, Gaute Ormåsen og Ben Adams er frokostgjester. De forteller om starten på Subwoolfer, ny barnebok og hva barna deres syns om duoen. Høstens 'Skal vi danse'-deltakere har blitt lansert - hva gjør de når det regner, utenom å danse? Premier League er rett rundt hjørnet, og Michael og Jan får quiz om fotball. Episoden kan inneholde målrettet reklame, basert på din IP-adresse, enhet og posisjon. Se smartpod.no/personvern for informasjon og dine valg om deling av data.

City Church AC Pastor Ben Adams 11:00 AM God's Ways are Far Above our Thoughts and Plans

This week, Canyon County Sheriff Kieran Donahue joins us to discuss challenges sheriffs are facing in recruiting and retaining deputies, and how that affects public safety. Then, Sen. Ben Adams, Rep. Julie Yamamoto, and House Minority Leader Ilana Rubel join Idaho Reports to discuss what lawmakers are working on in coming months.

The sudden failure of Silicon Valley Bank sent shock waves across global markets. Fierce Biotech Senior Editor Annalee Armstrong talked with Kiah Haslett, managing editor of the publication Bank Director, about how SVB's failure came to be and what to expect next. Armstrong and Fierce staff writer Max Bayer chat about how the biotech sector reacted given that SVB served almost half of all venture-backed technology and life sciences companies. They reflect on what surprised them as journalists covering the SVB news. Plus, in this episode, we cover Pfizer's blockbuster Seagen buyout, an expanded antibody-drug conjugate collaboration and more of this week's top headlines.  To learn more about the topics in this episode:  UPDATE: SVB failure triggers shock waves across biotech industry UK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK Insulet tapped to replace SVB on S&P 500 index after bank collapse Biden says America's 'banking system is safe' after regulators back up all SVB deposits With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' Synaffix, MacroGenics crack open ADC pact, tacking on $2.2B, 4 more programs Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US Lilly's 10-year bet on treating Alzheimer's before symptoms start ends in failure PerkinElmer completes $2.45B spinoff to create new diagnostics, life sciences company FDA oncology chief aims to open up accelerated approval for earlier cancer treatment under 'Project FrontRunner' Podnosis, a Fierce Healthcare podcast The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

In this interview with Ben Adams of 4T% Ranch, we dive deep into several subjects having to do with ranching, raising beef in Alaska, and even important things to consider if you're planning to buy a side of beef from an Alaskan rancher this year. PACKED with information, this podcast is for anyone wanting to gain a better understanding of Alaska-grown food, where your food comes from, and ideas on how we can all do better to bring our state to a place of true food independence. Here's how you can follow 4T% Ranch: Facebook: https://www.facebook.com/fourtpct Instagram: https://www.instagram.com/julianne.adams78/ YouTube: https://www.youtube.com/@4tfarmandranchalaska577

Some expect the next few years will be an overall down period for pharma growth. So, Fierce's Kevin Dunleavy invited Harietta Eleftherochorinou, Ph.D., of IQVIA to "The Top Line" to discuss why pharma needs to employ artificial intelligence and machine learning tools to stay ahead of the curve. To learn more about the topics in this episode:  2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products Covis finally pulls preterm birth drug Makena after 12-year accelerated approval odyssey FDA sounds out de novo clearance for neuromodulation device to treat tinnitus FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands Sarissa's overhaul of Amarin's board is complete with resignation of 7 holdover members AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff FDA delays BioMarin's gene therapy approval decision by 3 months The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Season 4 continues of the behind the scenes podcast SOAP FROM THE BOX, with a special spin off POP FROM THE BOX, where Lee Salisbury talks to some of the biggest music stars from the 80's, 90's and 00's. BEN ADAMS is not only lead singer with the hugely succesful A1, who reached Number One in the charts with their huge hit, CAUGHT IN THE MIDDLE, he is also a music writer and producer for stars such as CRAIG DAVID, ROBIN THICKE and ALEXANDRA BURKE. He has a new musical starting very soon and also reveals a a secret about Eurovision you may not know. SOAP FROM THE BOX is the ultimate TV behind the scenes podcast which already has over 75 episodes. Lee, TV Director and Producer, speaks to some of the biggest stars of the biggest shows. Head now to ANOTHER SLICE to get the whole show. You can find an exclusive bonus episode with EASTENDERS star Jacqueline Jossa plus extended episodes. We'll be back later this week with another brand new episode Learn more about your ad choices. Visit podcastchoices.com/adchoices

M&A plummeted in 2022 compared to the previous year. But some medtech companies were still able to pull off multibillion-dollar megadeals. We tracked it all on Fierce Medtech's list of the 10 biggest M&A moves in 2022. In this episode, we discuss some high points from the roundup.  To learn more about topics in this episode: The top 10 medtech M&A deals of 2022 Acquisitive Pfizer to strike again? Seagen back in M&A talks after Merck walked away: WSJ Eli Lilly slashes insulin prices by 70%, caps out-of-pocket costs in major access overhaul FDA hands first emergency authorization to over-the-counter test for both COVID and flu Sanofi, poised to rival Roche in hemophilia, nabs FDA approval for Altuviiio BioCryst hits another hurdle, delays trial for its one remaining clinical candidate The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

On this episode of the Justice Team Podcast, host Bob Simon and special guests Ben Adams, Eric Brown and Mark Bratt take a deep dive into the murky world of toxic torts. From the tragic event in East Palestine, Ohio, to harmful chemicals and polluted water, they're exposing the hidden dangers that big corporations don't want you to know.

Ben Adams, known as "imnotbenadams" online, is a dynamic musician and entrepreneur hailing from Utah. With a passion for music and an entrepreneurial spirit, Ben has made a name for himself in the local music scene. Currently a member of the EDM/Dance band, Southernmost Gravy, Ben has also played with The Johns and Backspun, showcasing his versatility as a musician.In addition to his music career, Ben is also an accomplished tour manager, having worked with national tours and artists. With a keen eye for talent, Ben recently launched the "Ben Adams Show", a platform that highlights a diverse range of musicians from different genres, including Freddie Dredd (rap), The Rare Occasions (indie/rock), Hotel Mira (alt/rock), and many more.Ben's unwavering dedication to music and his commitment to supporting local talent has earned him a reputation as a respected figure in the music community. With his creativity, passion, and entrepreneurial spirit, Ben Adams is a force to be reckoned with in the music industry. Hosted on Acast. See acast.com/privacy for more information.

In October 2022, the Society for Immunotherapy of Cancer released a checklist for running phase 3 cancer immunotherapy combination studies. SITC's aim with these guidelines is to maximize the value of these trials. In this episode, Fierce Pharma staff writer Angus Liu discusses the checklist with Dr. Michael Atkins, the first author. To learn more about topics in this episode: Moderna checks a few boxes in phase 3 mRNA flu shot trial, but misses on B strains and safety BD issues cybersecurity alert for hacking risk found in Alaris infusion pump software Apellis wins FDA approval for first geographic atrophy drug With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Last August, Moderna filed a lawsuit against Pfizer and its COVID-19 vaccine partner, BioNTech. Moderna claims that the partners copied its mRNA technology and infringed its vaccine patents. Pfizer wasn't going to sit back and take that. In September, the pharma giant dismissed the claims and accused Moderna of trying to rewrite the pandemic story to place itself in the “single, starring role,” the company's attorneys wrote in a scathing countersuit.    Kevin Noonan, Ph.D., is an intellectual property lawyer. He spoke with Fierce Pharma staff writer Zoey Becker to discuss what is likely to be the most significant patent fight from the pandemic era.    To learn more about topics in this episode: Clash of the titans: Moderna sues Pfizer, BioNTech for mRNA patent infringement Pfizer, BioNTech strike back at Moderna with mRNA vaccine patent lawsuit Moderna won't enforce COVID-19 vaccine patents during pandemic Pfizer CEO's texts with European Commission chief trigger new NYT lawsuit NuVasive, Globus Medical ink $3.1B orthopedic device merger, sending investors scrambling Big Pharma divided? Pfizer, AZ, Lilly and more support Sanofi in high-profile Amgen patent fight GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners Call for nominations: The most influential people in biopharma in 2023 The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

2022's slate of life sciences M&A deals didn't meet expectations. But the year still featured tens of billions of dollars worth of biopharma acquisitions. Querida Anderson and Eric Sagonowsky discuss the top deals of the year.  Also on the show, Kevin Dunleavy and Fraiser Kansteiner reflect on last year's largest buyout—Amgen's $28 billion deal for Horizon Therapeutics. They explore what it potentially means for the buyer's market this year. Plus, this week's top headlines and Max Bayer's and Kansteiner's scoop on Johnson & Johnson's R&D overhaul and layoff plans. To learn more about topics in this episode: The top 10 biopharma M&A deals of 2022 Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries Gilead's Trodelvy snags vital breast cancer nod. But AZ, Daiichi's Enhertu casts long shadow Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3 Call for nominations: The most influential people in biopharma in 2023 The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

It's confirmed: Ben Adams and Gaute Ormåsen are, in fact, Subwoolfer. The Norwegian singers (who sang "Give That Wolf A Banana" at Eurovision 2022) spoke with our Simon shortly after the final of Melodi Grand Prix 2023 in Trondheim. Interviewer: Simon - http://instagram.com/simonfalkdk

After a complicated 2022, the new year offers a course correction for the obesity market. We'll hear from Fierce's Fraiser Kansteiner and Querida Anderson on the numerous opportunities ahead in the obesity market.  Also on the show, Fierce's Kevin Dunleavy and Eric Sagonowsky reflect on the the 37 new drugs approved in 2022. Plus, this week's headlines.  To learn more about topics in this episode: 2023 forecast: With Novo's Wegovy on a supply rebound, 2023 offers course correction and obesity showdown with Lilly Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light Lilly's tirzepatide slides into FDA fast lane for obesity, turning up heat on Novo Nordisk's Wegovy 2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37 Time to shine, biosims: Amgen's Amjevita readies long-awaited assault on AbbVie's Humira Amgen's Humira biosimilar Amjevita hits the market with 2 different list prices In mysterious FDA approval, Pfizer quietly wins Ibrance breast cancer expansion Pfizer warns Comirnaty sales will plummet by nearly two-thirds in 2023. And Paxlovid won't fare much better Philips cuts another 6,000 jobs as CPAP recall, supply chain snags send 2022 sales down 3% Researchers predict Alzheimer's progression 3.5 years early with unique blood test The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Just last year, congress passed the Inflation Reduction Act. The law contains several drug pricing measures hated by the pharmaceutical industry, including restrictions to price increases and Medicare negotiations. Eric Sagnowsky talked with Stacie Dusetzina, a professor at Vanderbilt University's Department of Health Policy, about what we can expect.  Also on the show, Fierce's Analee Armstrong and Gabrielle Mason reflect on the biotech industry last year and our expectation for 2023—plus, this week's headlines.  To learn more about topics in this episode: 2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation' 2023 forecast: Biotech plummeted from 'the highest of highs' in 2022. Will the sun shine again next year? Fierce Biotech Fundraising Tracker: Enlaza launches with $61M; Enveda brings in $68M Fierce Biotech Layoff Tracker: Layoffs strike 119 companies in 2022 Theranos' Elizabeth Holmes labeled a 'flight risk' as she asks to delay prison sentence during appeal Eli Lilly shut out of Alzheimer's fast lane with FDA rejection for donanemab Health group lambasts CBS ‘60 Minutes' segment for overt promotion of Novo Nordisk's obesity med Wegovy Eli Lilly to pour $450M more into diabetes drug plant in North Carolina, add 100 jobs Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff and seek buyers for assets The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Fierce's JPM Week event was packed full of informative panels, executive interviews and fireside chats. So for today's episode, we've pulled out a couple of snippets to take you inside the gathering. First up, listen in on Fraiser Kansteiner's lively panel discussion on how companies will keep their bottom lines strong while navigating the drug pricing policies that the Biden administration rolled out just last year. You will also hear from Zoey Becker's interview with Bayer's Christine Roth. As head of the oncology strategic business unit, Roth talks about the plans to establish Bayer as a strong competitor in the cancer space. To learn more about topics in this episode: 2023 forecast: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation' To bolster IRA, lawmaker calls for new action to scrutinize cancer drug launch prices Pfizer, GSK, AbbVie and many more celebrate New Year with price hikes: report JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each Look out, Pfizer. With new approval, Bayer's Nubeqa is set to challenge Xtandi's prostate cancer crown Bayer's blockbuster hopeful Nubeqa debuts in later-stage prostate cancer in UK under early access program Bayer poaches GlaxoSmithKline exec to lead expanding oncology business—including a blockbuster hopeful Fierce JPM Week The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

The FDA is making some changes in the accelerated approval process. In this episode, we'll discuss the recent changes with the FDA's regulation of cancer drugs and how these shifts will impact the biopharma industry.   Also in this episode, we cover the week's biggest headlines from the annual J.P. Morgan Healthcare conference.  To learn more about topics in this episode: Fierce JPM Week Podnosis: The Pulse of the Healthcare Industry FDA wants confirmatory trials to be underway before granting accelerated cancer nods, Pazdur says Capitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout JPM23: Ipsen scoops up liver disease specialist Albireo for $952M Editas rewrites its own code after tough 2022, sending staff packing and editing down programs JPM23: Editas touts skinnier pipeline after major shake-up to ride out 'unfriendly' markets With Leqembi approval in Alzheimer's disease, Eisai and Biogen plot 'meticulous' launch AstraZeneca's first-in-class rescue inhaler Airsupra wins FDA nod—but only for adult use Baxter bids adieu to $5B kidney care division with spinout plan "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

There were a lot of moments in 2022 that left us scratching our heads. In this episode, we'll recap biotech's top blunders, boondoggles, gaffes and missteps in our "Rotten Tomatoes" report—plus, we highlight two ripened tomatoes that gave us hope.   Also in this episode, we cover the week's biggest headlines including drug approvals late in the last stretch of 2022, Moderna's first buy and why Biogen and the FDA are in hot water.  To learn more about topics in this episode: Fierce Biotech's Rotten Tomatoes of 2022 Roche gets FDA nod for Lunsumio, offering convenient option to gene therapies in follicular lymphoma After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca After FDA's Ukoniq pull, TG Therapeutics wins commercial mulligan with Briumvi to enter crowded MS arena Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report Moderna makes its first-ever acquisition, buying Japanese DNA manufacturer OriCiro for $85M Moderna CEO says mpox vaccine is 'fantastic.' It may never see the market GE HealthCare completes spinout into 'more focused, more agile' standalone company We're looking for the fiercest companies for Fierce Medtech's 2022 Fierce 15 Fierce JPM Week "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Connor Hale and Andrea Park as they discuss medtech's highest paid CEOs. Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting, and an update on the Horizon Therapudics bidding war.  To learn more about topics in this episode: Fierce JPM Week  The top 10 highest-paid medtech CEOs Fierce Biotech's ASH 2022 Coverage Fierce Pharma's ASH 2022 Coverage Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati  FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use  Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war  Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?  AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Idaho State Senator and former Marine Ben Adams joins Braxton to discuss Idaho exceptionalism, the heinous crime of sports betting, and tobacco inflation.

Last week, senior editor Annalee Armstrong and staff writer Gabrielle Mason covered the Clinical Trials on Alzheimer's Disease conference. We'll hear from them as they discuss the latest news and what surprised them.   Also in this episode, we cover the week's biggest headlines including an investigation into Neuralink, Google's DeepMind and why things aren't working out for PI3Ks. To learn more about topics in this episode: Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths Roche thins Alzheimer's program after phase 3 failure, may seek 'external partnerships' A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly Neuralink under federal investigation for animal testing practices: Reuters Elon Musk claims Neuralink is 6 months from implanting brain-computer interfaces in humans—and, someday, he'll be one of them 'Troubling' study finds Google's kidney disease-predicting AI performs worse in women—and may not have a quick fix In fresh blow to floundering PI3K space, FDA feedback drives MEI, Kyowa to halt blood cancer program Rigel scores green light in AML just 4 months after buying asset from Forma UPDATED: J&J bows out of Horizon bid as Amgen and Sanofi eye cash plays for rare disease drugmaker Pfizer plots €1.2B investment—and up to 500 new jobs—at Irish manufacturing plant Fierce JPM Week "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Biogen recently named Christopher Viehbacher its new CEO, ending a monthslong search to replace Michel Vounatsos. Fraiser Kansteiner and Kevin Dunleavy talk about the current state of the company and recent investor reactions to the new hire. Plus, they discuss a string of other biopharma CEO appointments.  And, in this episode, we cover the week's news including what Albert Bourla, Ph.D., said that has him in hot water along with a $3.5 million drug, and we tease a possible major acquisition.  To learn more about topics in this episode: Biogen's incoming CEO Viehbacher gets mixed reviews—and lots of advice—in investor survey  Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line  Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal  Facing a familiar side effect problem, Eisai makes the case for its next Alzheimer's drug after patient deaths Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A  Pfizer CEO Bourla stung by UK's pharma marketing regulator over kids' COVID vax claims: report  GE Healthcare unveils AI program bundle for simplified MRI scans Philips unveils AI-powered platform to improve diagnoses from imaging scans "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

This week on "The Top Line," we discuss 2022's Fiercest Women in Life Science honorees. Each year, we spotlight women who are leading the way in life sciences—women who stand out as leaders, innovators and mentors. We'll hear from Andrea Park and Querida Anderson on what it took to make the cut for this year's class of fiercest women in life sciences. Plus, this week's headlines.  To learn more about topics in this episode: 2022's Fiercest Women in Life Sciences Eli Lilly issues rare apology as fake Twitter Blue account proclaims free insulin for all Eli Lilly pulls Twitter ads after blue check fallout: report Roche's anti-amyloid antibody gantenerumab fails phase 3 in major blow to Alzheimer's ambitions NFL expands head injury research project using impact-tracking mouthguards, as concussion protocols come under fire Mayo Clinic launches digital referee for spotting potential bias in healthcare AI programs Four decades in, ImmunoGen gets landmark green light in advanced ovarian cancer Sanofi, GSK crash the COVID-19 vaccine party late with a world-first nod for their next-gen booster "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

This week on "The Top Line," we'll share highlights from the Cell & Gene Therapy Forum. Lack of access and multimillion-dollar costs have stirred debate over the appropriate price of potentially lifesaving cell and gene therapies. Fierce's Max Bayer spoke with a panel of stakeholders at the forum. They discussed the state of play for cell and gene therapies and how they can become a genuine game changer for the many, not the few. We also talk with executives from Poseida Therapeutics and AviadoBio.  To learn more about topics in this episode: Zolgensma for dementia? AviadoBio gains orphan tag for one-dose gene therapy  Poseida taps former Novartis VP as president of gene therapy  Fierce Biotech Summit: Disruptive gene technology is here—and society seems willing to pay for it Fierce Biotech Cell & Gene Forum "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Ben Adams grew up in the Elmwood Park neighborhood of Columbia, South Carolina. As a child, he couldn't wait to move to a larger city. Ben went to college in Washington, DC and then moved to New York City. During visits back to Columbia, he was impressed by the revitalization happening in Columbia's downtown. Eventually, Ben decided to move back to Columbia to pursue his dream of opening a bookstore. In early 2020, he opened Odd Bird Books in The Arcade Building, a recently restored shopping arcade on Columbia's Main Street that was built in 1912. In 2023, Odd Bird Books will be replaced by All Good Books, a bookstore in Columbia's Five Points neighborhood that Ben will be opening in partnership with Clint and Jenna Wallace.

It's earnings season again. Biogen offered a look at its second foray into Alzheimer's disease during its investor call, but listeners were still left dubious. All eyes—and ears—are on whether its lecanemab partnership with Eisai can outperform the ill-fated Aduhelm. In this episode, we chat about what went down during the earnings presentation, including rumors of a shaky relationship between the two drugmakers. We also explore AstraZeneca finally claiming an FDA approval for its long-troubled cancer immunotherapy Imjudo. The CTLA-4 drug has failed more than a few trials among different tumors over the years, and, now, it will enter a crowded and highly competitive liver cancer market.  UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization Despite Aduhelm cost cuts, Biogen still has Alzheimer's manufacturing firepower on deck, CFO says AstraZeneca's Imjudo finally snags first approval—only in an ever-crowded liver cancer field AIDS advocacy group hits out at 'Greediad' Gilead for drug pricing hikes J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy Medtronic to spin out respiratory, patient monitoring divisions amid flagging ventilator sales Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

We just released a special report on the top 10 vaccine companies. We haven't published this report since 2017, when we only profiled five manufacturers. But five years and one COVID pandemic later, that order has been completely shuffled with many new faces. It's clear that the vaccine industry is changing fast. In today's episode we'll discuss those global rankings, plus this week's headlines. To learn more about topics in this episode:  The top 10 vaccine companies worldwide Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule Atara on verge of landmark approval for first allogeneic T-cell therapy J&J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth As FDA rule takes effect, Lucid Hearing launches over-the-counter line of hearing aids The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

The world's most productive biopharmas have gone through some major changes in the past five years. In Fierce Pharma's latest analysis, BioNTech and Moderna beat their biopharma peers with the highest 2021 revenues per employee. The 2021 cohort as a whole showed improved productivity over 2016, although several companies experienced declines. In this episode, we'll discuss our special report on the most productive pharmas. Also under discussion is Biogen's tumultuous year, which was spurred by its disastrous Alzheimer's disease drug launch. Now Biogen is reportedly considering Theravance co-founder Mathai Mammen , M.D., Ph.D>, as its new CEO. The company supposedly wants to emphasize scientific know-how in choosing its next leader.  To learn more about topics in this episode:  The top 10 most productive biopharma companies J&J research vet Mathai Mammen a top contender in Biogen's hunt for a new CEO: Stat Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy AstraZeneca's COVID-19 nasal vaccine spray comes up a bust in small study Fitbit embeds health, activity data into Pretaa's substance abuse recovery app Merck & Co., in busy morning, taps Moderna's therapeutic cancer vaccine, Royalty in schizophrenia deal  Orthofix, SeaSpine to combine into $700M orthopedics player in merger of equals The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Eisai and Biogen's Alzheimer's disease drug lecanemab did surprisingly well in a phase 3 trial. The results support the idea that an anti-amyloid drug like lecanemab could be a way to treat Alzheimer's—a hypothesis that has been under fire since Biogen's debacle with its approved anti-amyloid med, Aduhelm. And, while lecanemab's approvability isn't being debated—unlike the case with Aduhelm after its phase 3 program read out—commercial reimbursement could still be a challenge for the Eisai drug. We'll also talk about football, or at least Pfizer's COVID vaccine ad campaign that kicked off during the NFL season. The company's marketing strategy over the last almost two years has changed over time and with various approvals. Recently, Pfizer ramped up its campaign with branded advertising for shots in teens, but its NFL season push is focused on its new, tweaked booster vaccine and takes a more subtle approach but with big money behind it.   To learn more about topics in this episode:  It's a hit: Eisai springs 'major surprise' with phase 3 win for Biogen-partnered Alzheimer's drug  Eisai and Biogen's phase 3 Alzheimer's win puts amyloid back in the driver's seat, for now Editor's Corner: Eisai and Biogen need to meet CMS halfway after lecanemab's Alzheimer's clinical trial win NFL season sees Pfizer kick off major Comirnaty COVID vaccine ad offensive for teens, boosters  Pfizer offers a soft sell with a strong message on vaccines in first COVID ad The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty Sign of the times? US stocks up on Amgen's radiation sickness drug Nplate  Capacity to spare: US has manufacturing firepower to crank out more essential medicines, researchers say  Illumina pitches $200 genomes with new line of DNA sequencers  Novo Nordisk ready to submit once-weekly insulin to FDA after scoring final phase 3 win  Ocaliva fails NASH trial just as Intercept charts path toward FDA application The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Ben Adams is a local representative for the State of Idaho. He was born in Jupiter, Florida and raised on the mission field in Kiev, Ukraine. As a pastor's son in Emmett, Idaho he was a home school graduate and is currently pursuing an undergraduate degree at Boise State University. He is a retired Marine Corps sergeant and served two combat tours in Afghanistan and one Marine expeditionary deployment as part of a battalion landing team. He is a Christian and married to his wife Rebecca and they have children, Dylan and Phoebe. Episode Talking Points: Growing up in Ukraine Life as a missionary kid Seeing God move in incredible ways Joining the Marines Afghanistan PTS and alcohol abuse Becoming an Idaho State Representative Links: Ben Adams' Twitter --- Support this podcast: https://anchor.fm/the-monday-christian/support

The next 3 weeks podcasts will be on location episodes. This week we got a chance to sit down with coaches at the California junior college championship in Folsom, CA. In this episode we will hear from Palomar’s Ben Adams, Ohlone’s Mike Curran, Riverside’s Rudy Arguelles, Folsom Lake’s Rich Gregory and CCCBCA President Chris Pedretti. This is a great time of the year with college championships going on. I appreciate coaches being willing to sit down in a hectic time for them getting their teams ready to compete for a championship. I am always impressed with the high level of baseball I see all over the country at every level of baseball. The ABCA Podcast is presented by Netting Pros. Netting Professionals are improving programs one facility at a time, specializing in the design, fabrication and installation of custom netting for backstops, batting cages, dugouts, bp screens and ball carts. They also design and install digital graphic wall padding windscreen, turf, turf protectors, dugout benches, dugout cubbies and more.